Diarrhea Clinical Trial
Official title:
Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases – A Phase IV Surveillance Study
For more than 25 years WHO and UNICEF have recommended a single formulation of glucose-based
Oral Rehydration Salts (ORS) to prevent or treat dehydration from diarrhoea irrespective of
the cause or age group affected. This product has proven effective and contributed
substantially to the dramatic global reduction in mortality from diarrhoeal disease during
the period.
Based on more than two decades of research and recommendations by an expert group, WHO and
UNICEF reviewed the effectiveness of a new ORS formula with reduced concentration of glucose
and salts. Because of the improved effectiveness of this new ORS solution WHO and UNICEF
recommended that countries use and manufacture this new formulation in place of the old one.
While recommending this new ORS the experts also recommended that further monitoring is
desirable to better assess the risk, if any of symptomatic hyponatraemia (low blood level of
sodium salt). This is a surveillance study to evaluate adverse effect of routinely using the
new ORS in a hospital admitting over 20,000 patients with diarrhea of all ages including
cholera. If the new ORS is found safe, it will provide added confidence in its global use.
It will be a Phase IV surveillance study of adverse effects, particularly symptomatic
hyponatraemia associated with routine use of hypo-osmolar ORS solution in the treatment of
diarrhoea patients of all ages and of any aetiology in a hospital that admits a large number
of diarrhoea patients.
Objectives: To monitor symptomatic hyponatraemia over a completed year in a hospital
treating a large number of patients with diarrhoea including cholera where all patients will
be treated with low osmolarity ORS
Study Design: It will be a phase IV surveillance study of adverse effects, particularly
symptomatic hyponatraemia associated with routine use of hypo-osmolar ORS solution in the
treatment of diarrhoea patients of all ages and of any aetiology in a hospital that admits a
large number of diarrhoea patients. Hypo-osmolar ORS as recommended by WHO is now being
routinely used for all patients admitted to a hospital which admits a large number of
diarrhoea patients including cholera. The hospital serves a metropolitan city and it’s
suburbs known to be endemic for cholera.
Hypothesis: We hypothesise that routine use of the recommended hypo-osmolar ORS will not be
associated with a significantly incidence rate of symptomatic hyponatraemia.
Study Site and Population: The study will be conducted in the Infectious Diseases Hospital,
Beliaghata, Kolkata. This hospital admits diarrhoea patients of all ages including cholera.
The hospital has 3 diarrhoea wards, one for adult men, one for adult women and one for
children. It is the designated hospital for admitting all clinically suspected cholera
patients from greater Calcutta. Of the total diarrhoea admissions during 1995 to 2002, a
little over 25% were children under five,
Duration: Total duration of the study will be 18 months.
Study subjects: The ID Hospital admitted approximately 23,000 patients with diarrhoea each
year for the years 2001 and 2002. We expect that similar number of patients with diarrhoea
will be admitted during the study period. We expect about 25 percent of them will be under
five children. Based on many clinical trials with hypo-osmolar ORS formulations, we expect
that symptomatic hypotraemia will be a rare event.
Inclusion Criteria: All patients admitted with diarrhoea over the study period of 12 months
will be eligible for the study, which include men, women and children.
Surveillances for the adverse events: Medical Officers on duty at the Diarrhoea Ward of I.D.
Hospital, under the supervision of a clinician scientist will look for the development of
symptoms like seizure, lethargy or altered consciousness, or marked irritability (i.e.,
irritable to touch). The investigations for these patients will include the determination of
blood glucose at bedside, serum electrolytes, and presence of fever. The decision to do a
spinal tap will be left to the clinician in-charge of the patients in the hospital. CSF and
blood culture will be done as and when indicated. Serum electrolyte measurements will be
made available round the clock.
Data analysis: Adverse events with particular reference to seizures, marked lethargy and
altered consciousness will be recorded. Their relation with hyponatraemia will be assessed
and the rates of such events associated with hyponatraemia will be compared (and 95%
confidence intervals will be calculated) with records from the preceding 12 months when the
patients received only standard WHO ORS with 90 mmol/L sodium.
Primary outcome measures: Symptomatic hyponatraemia. It is defined as biochemical
hyponatraemia associated with clinical features like convulsion or drowsiness or coma. A
serum sodium of less than 130 mmol/L will be considered as hyponatraemia and a serum level
less than 125 mmol/L will be considered as severe hyponatraemia.
Ethical Issues: The study will be conducted according to good clinical practice and the
Declaration of Helsinki and Indian Council of Medical Research Guidelines.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06283784 -
Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients
|
N/A | |
Recruiting |
NCT03851835 -
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
|
Phase 3 | |
Completed |
NCT04003181 -
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
|
N/A | |
Completed |
NCT03596827 -
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
|
N/A | |
Recruiting |
NCT05372068 -
Cement flooRs AnD chiLd hEalth (CRADLE)
|
N/A | |
Completed |
NCT03972618 -
Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT05052489 -
Registry and Clinical Observation of Children With Diarrhoeal Disease
|
||
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT02428647 -
Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT01968408 -
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
|
Phase 3 | |
Completed |
NCT01739231 -
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Not yet recruiting |
NCT01382199 -
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
|
Phase 3 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Terminated |
NCT01472211 -
Water-based Zinc Intervention Trial in Zinc Deficient Children
|
Phase 0 | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT00760851 -
Yogurt Study in Children 2-4 Years Old Attending Daycare
|
Phase 3 |